Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

NCT03888534 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision (no safety or efficacy concerns)

Conditions

Precursor Cell Lymphoblastic Leukemia-lymphoma

Interventions

DRUG: Ixazomib

Sponsor

Millennium Pharmaceuticals, Inc.